ANGLE plc (GB:AGL) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ANGLE plc has unveiled promising research indicating that its Parsortix system can effectively capture circulating tumor cells (CTCs) in prostate cancer patients, potentially aiding the development of targeted therapies. This breakthrough could enhance patient stratification in clinical trials, improving outcomes by tailoring treatments to specific biomarkers. With 67% of localized and 77% of treated patients showing positive biomarkers, ANGLE’s technology could revolutionize cancer treatment strategies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.